On May 11, 2026, aTyr Pharma Inc. reported a financial status of approximately $68.3 million in cash and investments as of March 31, 2026, and announced plans to continue developing efzofitimod for pulmonary sarcoidosis following FDA feedback, with a new Phase 3 study expected to involve 372 patients.